Novel evidence for m⁶A methylation regulators as prognostic biomarkers and FTO as a potential therapeutic target in gastric cancer.

ABSTRACT:

Background

While emerging evidence indicates that N⁶-methyladenosine (m⁶A) regulators play crucial roles in cancer progression, their clinical significance in gastric cancer (GC) has thus far not been elucidated.

Methods

We investigated the expression of the m⁶A regulator genes and their prognostic potential in a large clinical cohort of 173 GC patients using qRT-PCR assays. In addition, we undertook a series of in-vitro and in-vivo functional studies to investigate the oncogenic role of FTO.

Results

GC patients with low expression of METTL3, METTL14, ALKBH5, WTAP and YTHDF1 demonstrated significantly poor OS, while patients with high FTO expression exhibited markedly worse OS. Furthermore, the cumulative risk-score derived from these

SUBMITTER: Shimura T 

PROVIDER: S-EPMC8770595 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature